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Background: The prevalence of BRCA1 and BRCA2 mutations in Spain is heterogeneous and varies according to
geographical origin of studied families. The contribution of these mutations to hereditary breast and ovarian cancer
has not been previously investigated in Asturian populations (Northern Spain).
Methods: In the present work, 256 unrelated high-risk probands with breast and/or ovarian cancer from families
living in Asturias were analyzed for the presence of a BRCA1 or BRCA2 gene mutation from October 2007 to May
2012. The entire coding sequences and each intron/exon boundaries of BRCA1/2 genes were screened both by
direct sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA).
Results: A total of 59 families (23%) were found to carry a pathogenic germ line mutation, 39 in BRCA1 and 20 in
BRCA2. Twenty nine additional families (12%) carried an unknown significance variant. We detected 28 distinct
pathogenic mutations (16 in BRCA1 and 12 in BRCA2), of which 3 mutations in BRCA1 (c.1674delA, c.1965C>A and
c.2900_2901dupCT) and 5 in BRCA2 (c.262_263delCT, c.2095C>T, c.3263dupC, c.4030_4035delinsC,
c.8042_8043delCA) had not been previously described.
The novel mutations c.2900_2901dupCT in BRCA1 and c.4030_4035delinsC in BRCA2 occurred in 8 and 6 families
respectively and clustered in two separated small geographically isolated areas suggesting a founder effect. These 2
mutations, together with the Galician BRCA1 mutation c.211A>G (9 families), and the common BRCA1 mutation
c.3331_3334delCAAG (6 families), account for approximately 50% of all affected families. By contrast, very frequent
mutations in other Spanish series such as the BRCA1 Ashkenazi founder mutation c.68_69delAG, was found in only
one family.
Conclusions: In this study we report the BRCA1 and BRCA2 spectrum of mutations and their geographical
distribution in Asturias, which largely differ from other areas of Spain. Our findings may help design a first step
recurrent mutation panel for screening high-risk breast and/or ovarian cancer families from this specific area.
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Breast cancer is the most frequently diagnosed and the
leading cause of cancer death among females, accounting
for 23% of the total cases and 14% of the cancer deaths
[1]. While most tumors are sporadic, about 5 to 10%
are caused by germ line mutations in certain genes [2].
BRCA1 (MIM 113705) [3] and BRCA2 (MIM 600185) [4]
genes are responsible for approximately 20-40% of
inherited breast cancer [5,6]. Women carrying germ line
mutations in these genes have a high lifetime risk of deve-
loping both breast and ovarian cancer [7]. Testing these
high-penetrant genes can make it feasible to identify indi-
viduals at risk as candidates for surveillance programs [8].
Prevalence of BRCA1 or BRCA2 germ line mutations
varies considerably among ethnic groups, and in some
countries, founder mutations are responsible for a signifi-
cant proportion of breast cancer cases. Specific mutations
have been described, for example, among Ashkenazi Jews,
in Iceland, and in several other countries where isolated
populations exists [9]. Mutational analysis of BRCA1 and
BRCA2 in hereditary breast and ovarian cancer families
have also been reported in several Spanish regions, show-
ing a heterogeneous prevalence of recurrent mutations
according to the geographical area [10]. However there
are to date no comprehensive studies in the Asturian
population, a geographically isolated area in the North
of Spain.
In this article, we present mutation detection data
corresponding to a set of 256 high-risk families living
in Asturias, analyzed by direct sequencing and MLPA.
Thirty-nine families were found to have a mutation in
BRCA1 gene and 20 in BRCA2. We report the finding
of 8 novel mutations and the clustered geographical




Patients were referred to the Familial Cancer Unit at
Hospital Universitario Central de Asturias (HUCA) for
genetic counseling by physicians between October 2007
and May 2012. Information about the number and type
of cancers, age of diagnosis, age of death or current age
and geographical origin were collected from each fam-
ily. Genetic testing was offered to affected individuals
from high-risk families meeting any of the following
criteria:
A. Three or more family members with breast and/or
ovarian cancer.
– A. Br: only breast cancer.
– A. Ov: at least one ovarian cancer.
B. Two family members with ovarian cancer.C. One family member with ovarian cancer and one
with breast cancer.
D. One family member with a male breast cancer and
one or more with breast and/or ovarian cancer.
E. Two family members with breast cancer, before the
age of 50.
F. One family member with bilateral breast cancer
and one with breast cancer, at least one before the
age of 50.
G. Single affected individual with either:
– Ga: bilateral breast cancer, first diagnosed before
the age of 40, or
– Gb: breast or ovarian cancer diagnosed before
the age of 30, or
– Gc: breast and ovarian cancer
H. Affected probands from families close to fulfill any
of the above criteria. We have included in this
group affected probands with a history suggestive
of hereditary breast and ovary cancer who do not
fulfill completely any of the above inclusion
criteria. This included, for instance, probands from
small families with two affected relatives older
than 50 years of age with triple negative breast
cancer.
A total of 256 families fulfilled any of the selection cri-
teria. The study was approved by the hospital ethical com-
mittee. All tested individuals provided a signed informed
consent following appropriate genetic counseling. Blood
samples were obtained from at least one affected member.
DNA and RNA were obtained from peripheral blood from
all studied members of the family. Index case was first
analyzed for large genomic rearrangements and then for
sequence mutations. Genomic DNA was obtained after
red blood cell lyses using DNAzol method (MRC, USA).
RNA was purified from leucocytes by using TriReagent
solution (Ambion, Life Technologies).
Large genomic rearrangements of BRCA1 and BRCA2
BRCA1 and BRCA2 large genomic rearrangements
were assayed by MLPA (multiplex ligation-dependent
probe amplification) by using P002 and P087 kits for
BRCA1 gene and P045 kit for BRCA2 gene (MRC-
Holland), following essentially the instructions of the
manufacturer. Amplified products were electropho-
retically separated in an ABIPrism310 genetic analyzer
and interpreted using the GeneMapper 4.0 software
(Applied Biosystems). For normalizing the data, at
least two genomic DNA samples obtained from
peripheral blood cells of healthy donors were always
run as controls in each analysis. Quantification of the
results, measuring peak areas, was performed by using
an Excel calculation sheet. The final allele dosage for
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(“n” peak area from sample / “n” peak area from control)
divided by (∑ reference peak areas from sample / ∑ re-
ference peak areas from control).
Normal values were considered when this ratio was
between 0.8 and 1.2.
Mutation analysis of BRCA1 and BRCA2
Mutational screening of BRCA1 and BRCA2 genes was
performed by direct sequencing of each exon and 20 bp
exon-intron boundaries, by standard Sanger sequencing
using BigDye™ terminator sequencing kits (Applied
BioSystems). Sequence analyses for some index cases
were performed at Sistemas Genómicos SL (Valencia,
Spain) or at Imegen (Parque Científico, Universidad de
Valencia, Spain).
Reference sequences used for BRCA1 and BRCA2
analyses were GenBank NM_007294.2 (BRCA1) and
NM_000059.3 (BRCA2). Mutation nomenclature is de-
scribed according to Human Genome Variation Society
(v2.0) (www.hgvs.org) [11].
Results and discussion
Frequency of families with BRCA1 and BRCA2 pathogenic
mutations according to the inclusion criteria
We identified 59 families carrying a pathogenic muta-
tion, 39 in BRCA1 and 20 in BRCA2, which represent
23% of all screened families (Table 1). The highest muta-
tion detection rate in BRCA1 was observed in families
with at least one ovarian cancer (groups A.Ov., B, C, and
Gc.) and in families with a single case of bilateral breast
cancer diagnosed before the age of 40 (group Ga). Re-
garding BRCA2, the highest detection rate was observed
in families with one breast cancer and one ovarian
cancer and in families with a male breast cancer (groupsTable 1 Frequency of families with BRCA1/2 pathogenic muta
Family type Tested families BRCA1
A. Br. (3 or >, only Br) 80 5
A. Ov. (3 or >, at least 1 Ov) 48 16
B. 2 Ov 2 1
C. 1 Br + 1 Ov 33 9
D. 1 mBr and Br/Ov 11 1
E. 2 Br<50 35 3
F. bBr and other <50 13 1
G. a. 1 bBr<40 2 1
G. b. 1 Br<30 9 0
G. c. 1 BrOv 4 1
H. borderline 19 1
Total 256 39
Br, breast cancer; Ov, ovarian cancer; mBr, male breast cancer; bBr, bilateral breast cC and D), while mutations were not found in any of the
groups with single cases (group G) or two ovarian can-
cers (group B). Three out of 11 families with a male
breast cancer (group D) carried a pathogenic mutation,
1 in BRCA1 and 2 in BRCA2. These mutation detection
rates are comparable to previously reported populations.
No pathogenic mutations were found in 9 women with
early onset breast cancer without family history (group
Gb). Although this is an inclusion criterion in all clinical
guides, other authors have also found very low mutation
rate in this group [12,13]. On the other hand, we identi-
fied a deleterious mutation in 2 out of 19 affected
probands (10.5%) who did not fully meet our present
inclusion criteria for testing. Within this group (H), a
BRCA1 deleterious mutation was found in a family with
two affected first degree relatives diagnosed with breast
cancer over the age of 50, having one of them a “triple
negative” phenotype in the tumor. The other proband
was a 47-year-old woman, diagnosed with ovarian cancer
and with no family history of cancer, in whom a BRCA2
pathogenic mutation was identified.
BRCA1 deleterious mutations
Analysis of the BRCA1 gene revealed 16 distinct germ
line mutations with predicted deleterious effects on the
BRCA1 protein in 39 families (Table 2). Among these
pathogenic mutations, 3 are novel and have not yet been
reported in the Breast Cancer Information Core, BIC
(http://research.nhgri.nih.gov/bic/). One of these novel
BRCA1 mutations, c.2900_2901dupCT (p.Pro968Leufs),
was shared by 8 apparently unrelated families and it
accounted for 20% of BRCA1 mutated families. This
mutation is responsible for 7 breast and 7 ovarian cancer
cases. Mean age of diagnosis was 49 years (range 33–78)
for breast and 53 years (range 41–82) for ovarian cancer.
Clinical and pathological characteristics of these families
are shown in Table 3. The two remaining BRCA1 noveltions according to the inclusion criteria
(%) BRCA2 (%) BRCA1/2 (%)
(6.3) 6 (7.5) 11 (13.8)
(33.3) 4 (8.3) 20 (41.7)
(50.0) 0 (0.0) 1 (50.0)
(27.3) 4 (12.1) 13 (39.4)
(9.1) 2 (18.2) 3 (27.3)
(8.6) 2 (5.7) 5 (14.3)
(7.7) 1 (7.7) 2 (15.4)
(50.0) 0 (0.0) 1 (50.0)
(0.0) 0 (0.0) 0 (0.0)
(25.0) 0 (0.0) 1 (25.0)
(5.3) 1 (5.3) 2 (10.5)
(15.2) 20 (7.8) 59 (23.0)
ancer.
Table 2 Germ line BRCA1 pathogenic mutations in breast and ovarian cancer families from Asturias
Exon BIC nomenclature HGVS nomenclature Predicted effect N families Families origen Comments
2 185delAG c.68_69delAG p.Glu23Valfs 1 Asturias Ashkenazi Founder
5 330A>G c.211A>G p.Arg71Gly 9 Galicia Galician Founder
8 589delCT c.470_471delCT p.Ser157* 3 Asturias Spain/Worldwide
11 910del4 c.791_794delGTTC p.Ser264Metfs 1 Castilla/León Spain
11 c.1674delA p.Gly559Valfs 1 Asturias Novel
11 1806C>T c.1687C>T p.Gln563* 1 Castilla/León Spain/Sweden Founder
11 c.1965C>A p.Tyr655* 1 Asturias Novel
11 c.2900_2901dupCT p.Pro968Leufs 8 Asturias Novel
11 3450del4 c.3331_3334delCAAG p.Gln1111Asnfs 6 Several Spain/Worldwide
11 3808T>G c.3689T>G p.Leu1230* 1 Castilla/León Spain/Portugal
11 3889delAG c.3770_3771delAG p.Glu1257Glyfs 2 Several Spain/Worldwide
11 4184del4 c.4065_4068delTCAA p.Asn1355Lysfs 1 Asturias Worldwide
18 5236G>C c.5117G>C p.Gly1706Ala 1 Asturias Spain/Europe
LARGE GENOMIC REARRANGEMENTS
1 -24 BRCA1 del Ex 1-24 1 Asturias Spain/Europe
1-13 BRCA1 del Ex 1-13 1 Asturias Spain/Europe
20 BRCA1 del Ex 20 1 Asturias Europe
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(p.Tyr655*) were found only in one family each.
Among previously described mutations in BRCA1, the
most common was the mutation c.211A>G (p.Arg71Gly),
which was present in 9 families in our series (23%). This
mutation is a founder mutation in Galicia, a Spanish re-
gion located just alongside western Asturias, where it
represents 50% of all mutations [14,15], but it is almost
absent in other Spanish populations [10]. All families
found in our study to carry this mutation were either from
Galicia or had Galician ancestors. Another commonTable 3 Clinic pathological characteristics of tumors from ind
(p.Pro968Leufs)
Family.individual Sex Age Tumor Histopath
42.1 F 52 Ov Endome
42.5 F 82 Ov Serou
72.1 F 54 Ov Undifferentiate
72.2 F 33 Br Undifferen
215.1 F 41 Ov Serou
263.1 F 56 Ov Serou
458.1 F 43 Br IDC
458.2 F 51 Br IDC
572.1 F 41 Ov Serou
704.1 F 49 Br IDC
828.1 F 48 Br IDC
78 Br IDC
828.2 F 42 Br IDC
828.3 F 45 Ov -
Age age of cancer diagnosis, F female, Br breast cancer, Ov ovarian cancer, IDC inva
status, Her2 Her2Neu status, - not applicable or no data, Neg negative, Pos positivemutation, the c.3331_3334delCAAG (p.Gln1111Asnfs),
was found in 6 families, thus representing 15% of BRCA1
mutated families. It was first described in 1996 in a
Canadian family [16] and thereafter in populations
from all over the word. More recently an haplotype
analysis performed in Hispanic populations living in
Colombia suggested that this mutation has arisen from
a common ancestor and that could represent a founder
effect of Spanish origin [17]. This common mutation
has 40 records in the BIC database, and has been reported
in other regions of Spain [18,19]. The c.470_471delCTividuals carrying the BRCA1 mutation c.2900_2901 dupCT
ology Stage Grade ER PgR HER2
trioid IIIC - - - -
s IIIC - - - -
d/Mucinous IC 3 - - -
tiated IIIA 3 Neg Neg Neg
s IIIC 3 - - -
s IIIB 2 - - -
II 3 Neg Neg Neg
III 3 Neg Neg Neg
s IIIC - - - -
IIIA - Neg Neg -
I - Pos Pos -
IA 3 Pos Pos Neg
IIA 3 Pos Pos -
- - - - -
sive ductal carcinoma, ER estrogen receptor status, PR progesterone receptor
.
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being also reported in other Spanish [20,21], Chinese [22]
and in Portuguese populations [23].
Other previously reported mutations were less frequent
in our study. Thus, the nonsense mutation 1687C>T
(p.Gln563*) was found in one family originally from León,
Spain. Although this mutation was first described in 1996
in a Swedish population where it was considered to have
a founder effect [24], it has also been reported in the
Spanish area where this family came from (Castilla-León)
[21]. From the same region were also two families carrying
the mutations c.791_794delGTTC (p.Ser264Metfs) and
c.3689T>G (p.Leu1230*). Both mutations have been pre-
viously reported in Spanish populations [15,20], as well as
the mutation c.3770-3771delAG (p.Glu1257Glyfs), found
in two families from our study.
Notably, the frame shift mutation c.4065_4068delTCAA
(p.Asn1355Lysfs), which is one of the most frequently
reported (133 entries in BIC) [25,26], was only found in
one of our families and has not been previously reported
in Spain. The Ashkenazi founder mutations c.68_69delAG
(p.Glu23Valfs) was found in only one family, while it is the
most frequent BRCA1 alteration found in other Spanish
series [20]. Finally, we found the missense mutation
c.5117G>C (p.Gly1706Ala) in one family. Although this
mutation is still annotated as one with unknown clinical
importance in the BIC database, some studies support that
it could be pathogenic [20,27].
BRCA1 large genomic deletion
An MLPA-based search for large genomic rearrangements
was performed in all index cases. This approach revealed
that three of them were positive for the presence of a large
deletion in the BRCA1 gene. One family presented hetero-
zygous deletions for all the probes specific for BRCA1,
from exon 1 to exon 24, revealed with two different MLPA
kits (P002B and p084). The index case was a 56 years old
woman with ovarian cancer. Her mother had also ovarian
cancer and a sister was affected of breast cancer. After a
complete study of all available members of the family, we
could confirm that the deletion segregated with the dis-
ease. BRCA1 complete deletions have only been previously
reported in 3 families, being a de novo mutation in one of
them [28-30].
A second case showed an MLPA profile suggesting
heterozygous deletions in probes specific for exons 1 to
13. The pattern was displayed with probes from P002B
kit and confirmed with P082 MLPA kit exons 1–13. The
deletion was identified in a woman with ovarian cancer
at the age of 64 who had had a bilateral breast cancer at
ages 42 and 61 respectively. Her sister had also had an
ovarian cancer at the age of 33. This mutation has also
been described in another Spanish family [31] and in
one from Finland [32], both with cases of ovarian cancer.Finally, we found an in frame deletion in exon 20 in a
large family. More detailed data about this deletion will
be reported elsewhere (manuscript in preparation).
Deleterious BRCA2 mutations
Analysis of the BRCA2 gene revealed 12 distinct germ line
mutations with predicted deleterious effects on the BRCA2
protein in 20 families (Table 4). Among these pathogenic
mutations 5 have not yet been reported in the Breast
Cancer Information Core, BIC. Thus, the novel truncating
mutation c.4030_4035delinsC (p.Asn1344Hisfs), shared by
6 families, is BRCA2 most frequent mutation in our series
and accounts for 30% of the BRCA2 mutations. In the
eleven carriers identified, a total of ten breast cancers, three
ovarian cancers and one squamous oesophagus cancer
have been diagnosed. Median age at diagnosis was 48 for
breast (range 32–74) and 52 for ovarian cancer (range
48–60). Clinic and pathological characteristics of tumors
from individuals carrying this mutation are shown in
Table 5.
The second most frequent novel mutation in BRCA2 was
c.2095 C>T (p.Gln699*) identified in three Asturian fam-
ilies, while the following novel truncating mutations were
found in one family each: c.262_263delCT (p.Leu88Alafs);
c.3263dupC (p.Gln1089Serfs); and c.8042_8043delCA
(p.Thr2681Serfs). Individuals with these 3 novel mutations
come either from Andalucía (Southern Spain) or from
Albacete (Eastern Spain) where, to our knowledge, a com-
prehensive mutational analysis has not been reported yet.
Eight families carried 7 previously reported BRCA2
mutations. Two families carried the mutation c.1813dupA
(p.Ile605Asnfs), which is very common in Western Europe,
mostly in Germany where a possible founder effect has
been suggested [33]. The other 6 known mutations were
found in one family each. The c.5116_5119delAATA
(p.Asn1706Leufs) and c.9310_9311delAA (p.Lys3104Valfs)
mutations, recurrent in Castilla-León, were found in two
families originally from that area [34]. The pathogenic mu-
tation c.5576_5579delTTAA (p.Ile1859Lysfs) was found in
one family from the País Vasco (Northern Spain) and has
been previously described in other Spanish populations
[13,35]. Another family carried the frame-shift mutation
c.4631dupA (p.Asn1544Lysfs), which has also been de-
scribed in Western European populations [36]. The frame-
shift c.9026_9030delATCAT (p.Tyr3009Serfs), which is a
founder mutation originating in the Northeast of Spain
[37], was identified in one family from Cantabria (Northern
Spain). Finally, an African American woman with early on-
set bilateral breast cancer carried the nonsense mutation
c.2830A>T (p.Lys944*), which has 6 entries in the BIC
database and has been found in a Swedish series [38] but
has not been previously reported in the Spanish population.
In contrast to the large BRCA1 genomic deletions
discussed above, no large genomic rearrangements were
Table 4 Germ line BRCA2 pathogenic mutations in breast and ovarian cancer families from Asturias
Exon BIC nomenclature HGVS nomenclature Predicted effect N families Families origen Comments
3 c.262_263delCT p.Leu88Alafs 1 Andalucía Novel
10 2041insA c.1813dupA p.Ile605Asnfs 2 Asturias Worldwide
11 c.2095 C>T p.Gln699* 3 Asturias Novel
11 3058A>T c.2830A>T p.Lys944* 1 Dominican Republic Worldwide
11 c.3263dupC p.Gln1089Serfs 1 Albacete Novel
11 c.4030_4035delinsC p.Asn1344Hisfs 6 Asturias Novel
11 4859insA c.4631dupA p.Asn1544Lysfs 1 Asturias Europe
11 5344del4 c.5116_5119delAATA p.Asn1706Leufs 1 Castilla/León Castilla/León, Founder
11 5804del4 c.5576_5579delTTAA p.Ile1859Lysfs 1 País Vasco País Vasco
18 c.8042_8043delCA p.Thr2681Serfs 1 Andalucía Novel
23 9254del5 c.9026_9030delATCAT p.Tyr3009Serfs 1 Cantabria Cataluña, Founder
25 9538delAA c.9310_9311delAA p.Lys3104Valfs 1 Castilla/León Castilla/León, Founder
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our study.
Unclassified variants
Twenty two different variants of unknown significance
were identified in a total of 29 affected index cases, 3
of which had not been previously reported, 2 in
BRCA1 and 1 in BRCA2 (Table 6). The BRCA1 mis-
sense mutation c.287A>C (p.Asp96Ala) has no BIC re-
cords, although the mutation p.Asp96Asn in the same
position is considered pathogenic by some authors due
to the fact that this amino acid is fully conserved
throughout evolution [39]. We could not perform co-
segregation studies, as the only first degree relative with
cancer was deceased at the time of the study. The secondTable 5 Clinic pathological characteristics of tumors from ind
(p.Asn1344Hisfs)
Family.individual Sex Age Tumor Histopath
27.1 F 52 Br IDC
60 Ov Serou
27.2 F 32 Br IDC
27.3 M 60 Es Squamo
208.1 F 50 Br ILC
57 Br IDC
208.2 F 74 Br -
331.1 F 48 Ov Serou
331.2 F 49 Br ILC
424.1 F 50 Ov Serou
609.1 F 43 Br IDC
43 Br DCIS
795.1 F 42 Br IDC
795.2 F 39 Br IDC
Age age of cancer diagnosis, F female, M male, Br breast cancer, Ov ovarian cancer
carcinoma, DCIS ductal carcinoma in situ. ER estrogen receptor status, PR progester
negative, Pos positive.novel BRCA1 variant is the c.656A>T (p.Asp219Val)
found in a family with 6 breast cancers. Two bioinformat-
ics tools, Sorting Intolerant From Tolerant (SIFT) [40]
and Polymorphism Phenotyping (PolyPhen) [41] indi-
cate that this variant may alter the function of the
protein. However, this variant does not segregate with
the disease in this family and the affected residue is
not conserved in mammals. A novel BRCA2 variant
found in the present work is the missense mutation
c.6847C>A (p.Pro2283Thr), affecting a conserved resi-
due in chordates. According to the above bioinfor-
matics tools, this variant could be also pathogenic but
it did not segregate with the disease in a family with
two ovarian cancers. Consequently, these two variants
are probably non-pathogenic.ividuals carrying the mutation: BRCA2 4258_4263delinsC
ology Stage Grade ER PgR HER2
I 3 Neg Neg -
s IC - - - -
IIB 3 Neg Neg Pos
us III - - - -
ND - - - -
ND - - - -
IIIB - - - -
s IV 3 - - -
I Pos Pos Neg
s IC 2 - - -
IIIA - Pos Pos Neg
- - - -
IIA - Pos Pos -
IV - Pos Pos -
, Es esophagus cancer, IDC invasive ductal carcinoma, ILC invasive lobular
one receptor status, Her2 Her2Neu status, - not applicable or no data, Neg
Table 6 BRCA1 and BRCA2 variants of unknown significance detected in breast and ovarian cancer families from
Asturias
Gene Exon BIC nomenclature HGVS nomenclature Predicted effect Nº families Reference
BRCA1 3 234T>A c.115T>A p.Cys39Ser 1 BIC, LOVD
5 318G>T c.199G>T p.Asp67Tyr 2 BIC, LOVD
6 c.287A>C p.Asp96Ala 1 Novel
10 c.656A>T p.Asp219Val 1 Novel
11 1186A>G c.1067A>G p.Gln356Arg 1 BIC, LOVD
11 4158A>G c.4039A>G p.Arg1347Gly 1 BIC, LOVD
15 4654G>T c.4535G>T p.Ser1512Ile 1 BIC, LOVD
16 5075A>A c.4956G>A p.Met1652Ile 2 BIC, LOVD
17 5173C>T c.5054C>T p.Thr1685Ile 1 BIC, LOVD
19 5273G>T c.5154G>T p.Trp1718Cys 2 BIC, LOVD
21 IVS20-6_IVS20-4del c.5278-6_5278-4del No effect 1 Campos et al. [42]
22 IVS21-8C>T c.5333-8C>T Unkown 1 BIC
BRCA2 3 IVS2-T7>A) c.68-7T>A p.Asp23_Leu105del 2 BIC, LOVD
10 c.1714G>A p.Val572Ile 1 UMD-BRCA2
11 6110G>A c.5882G>A p.Ser1961Asn 1 BIC
11 6328C>T c.6100C>T p.Arg2034Cys 2 BIC, LOVD
11 6976A>G c.6748A>G p.Thr2250Ala 1 BIC, LOVD
11 c.6847C>A p.Pro2283Thr 1 Novel
18 c.8023A>G p.Ile2675Val 1 UMD-BRCA2, LOVD
20 8731T>C c.8503T>C p.Ser2835Pro 2 BIC, LOVD
22 9078G>T c.8850G>T p.Lys2950Asn 1 BIC, LOVD
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reported, controversies persist in the literature regarding
the pathogenicity of some of them. This is the case of mis-
sense mutation c.115T>A (p.Cys39Ser), which is regis-
tered as a variant of unknown significance in the BIC
database, but alters the protein structure and is considered
deleterious by some authors [39,43]. We found it in a fam-
ily with breast and ovarian cancer, but it did not segregate
with the disease as it was not present in one of the sisters
who developed breast cancer at the age of 33. On the
other hand, two BRCA1 missense variants, c.5054C>T
(p.Thr1685Ile) and c.5154G>T (p.Trp1718Cys), affecting
highly conserved amino acid residues, have been predicted
to be deleterious by a number of studies, including a
multifactorial likelihood-ratio model [44], evolutionary
conservation analyses and functional assays [39,45,46]. In
our population, we could not study co-segregation of
those variants, but the number of coincident results in
favor of causality suggests that these variants can be
deleterious.
We found the nonsense mutation c.9976A>T (p.Lys3326*)
in two unrelated families. In spite that this mutation intro-
duces a stop codon, causing premature termination ofthe protein, it is considered in BIC as with no clinical sig-
nificance. In agreement with these observations, this
mutation does not segregate with the disease in one of the
families studied in this work. Some other variants are
probably non-pathogenic, with odds of >100:1 in favor
of neutrality according to multifactorial model by Easton
et al. [44]. This can be the case of BRCA1 c.199G>T
(p.Asp67Tyr) and BRCA2 c.6748A>G (p.Thr2250Ala) and
c.8850G>T (p.Lys2950Asn).
Geographic distribution of two novel recurrent mutations
Asturias is a Northern Spain community of 1 million in-
habitants, bordered by Galicia to the West, Cantabria to
the East and Castilla-León to the South. It has been
rather isolated from the rest of Spain by its high moun-
tains and it was one of the few areas that never came
under the Muslim control that lasted in most of the
Iberian Peninsula for five centuries. Although modern
society has made possible migration phenomena, small
geographically isolated communities still remain within
deep valleys in a rural environment.
The origin of the eight families with the c.2900_
2901dupCT (p.Pro968Leufs) BRCA1 novel mutation
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coastline to the mountains bordering the province of
Leon to the South (Figure 1). An historical important
roman pathway (Calzada de la Mesa) communicating
these two regions is found in the vicinity. This is the
area where Vaqueiros, a seasonal transhumance popula-
tion were established. With different habits and their
own dialect, they have been for centuries a distinct social
group, suggesting a possible founder effect of this
mutation.
Regarding the other recurrent mutation c.4030_
4035delinsC (p.Asn1344Hisfs) in BRCA2, the six families
with this mutations were from a small area situated on
the western border of Asturias (Figure 1), geographically
isolated by two deep river valleys (Eo and Navia rivers)
running from South to North. Interestingly, the popula-
tion living there has their own and distinct dialect
called Eonavian confirming the isolation and thus







Figure 1 Map of Asturias showing the geographical origin of the fam
mutations. Two main linguistic areas are separated by a solid line while d
with data from dialectologists Zamora-Vicente and Fernandez-Rei). BRCA1 c
population established in the vicinities of a Roman pathway of historical im
Eonavian dialect population.Conclusions
In this study we conducted for the first time a compre-
hensive BRCA1/2 screening in a group of 256 high risk
families living in Asturias. We found that 59 families
carried a pathogenic mutation, 39 in BRCA1 and 20 in
BRCA2, 8 of them being novel. Two mutations were
found in families who cluster in two geographical and
customary isolated areas, suggesting a founder effect,
although future haplotype analysis would be necessary
to confirm this hypothesis. Besides, all the families who
carried the previously reported Galician founder muta-
tions had Galician ancestors. In total, these three muta-
tions plus a known recurrent mutation account for
approximately 50% of all affected families, being 60% of
BRCA1 and 30% of BRCA2 mutations recurrent. The re-
sults of the present study suggest that Asturias belongs
to the group of geographical areas in which a small







ilies with the two most frequent novel BRCA1 and BRCA2
ialect boundaries are separated by dotted lines (based in map created
.2900_2901dupCT mutation can be related to a transhumance
portance while c.4030_4035delinsC BRCA2 is closely associated to
Blay et al. BMC Cancer 2013, 13:243 Page 9 of 10
http://www.biomedcentral.com/1471-2407/13/243Consequently, testing a person from these areas for
their respectively recurrent mutations before sequencing
the complete genes could be a cost and time-efficient
way to assess if the individual has BRCA1 or BRCA2
germ line mutations. Finally, we believe that conducting
a specific mutational analysis on unselected cases of
both breast and ovarian cancer for the Asturian women
whose origin are these two small areas where the novel
mutations seem to cluster, may be helpful and effective
in cancer prevention terms.
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